The utility software provider has contributed to the $33m first close of venture firm Vendep's Vendep Capital Fund II, which has secured Tesi as a cornerstone investor.

Novartis Venture Fund co-led the gene therapy developer's series A round, which also included funding from Roche Venture Fund.

The wind turbine manufacturer is keen on making minority investments in energy storage technology developers.

Total and Bridgestone have contributed to a $13.2m funding round for car analytics technology developer and Mobivia spinout Xee.

Boehringer Ingelheim Venture Fund has co-led a $21.8m round for ImCheck Therapeutics, which announced its new CEO in conjunction with the funding.

Cambridge Enterprise and Cambridge Innovation Capital both participated in the funding round, which is based on research at the Cambridge Institute for Medical Research.

Sosei will pay $45m for a 25% stake in RNA therapy developer Mina Therapeutics and could buy the NTNU spinout outright for about $180m more.

Exploiting research conducted at Navarra University and Harvard Medical School, Vivet Therapeutics is working on gene therapies for metabolic diseases.

Sosei will pay $45m for a 25% stake in RNA therapy developer Mina Therapeutics and could buy the company outright for about $180m more.

France-based venture firm Elaia Partners has reached the first close of its fourth fund, with EDF, Nexity, ADP and Mgen all contributing capital.